SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, that is used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes
The medication also slows gastric emptying, meaning food moves through your stomach more gradually and enters your bloodstream at a slower rate
Some patients respond better to one medication over the other regardless of clinical averages
These findings suggest factors other than semaglutides glucose-lowering effects are responsible for this reduction in MACE risk, Dr
Alkhouri N, Loomba R, Frias JP, et al
GLP-1 drugs are FDA-approved for patients with obesity, those who are overweight with related health conditions and those with specific health issues